In recent years, the medical cannabis market has grown significantly, reflecting global trends and growing interest in the therapeutic properties of cannabis. This trend is particularly evident in light of recent financial reports from leading companies such as Canadian giant Aurora Cannabis. In the second quarter of this year, the company reported record growth in revenue and pre-tax profits, marking a watershed moment for the entire industry.
Aurora Cannabis, a leader in the medical cannabis market, reported a significant increase in net income in the third quarter of 2023, reaching C$63.4 million, up 30% year-on-year. A key contributor to this growth is the expansion of the company’s global medical cannabis business, where sales rose 42% to C$43.8 million. Aurora’s European medical cannabis business saw significant increases, mainly due to the introduction of new, proprietary, effective cannabis strains and increased sales to Australia.
Aurora Cannabis also reported positive EBITDA (earnings before interest, taxes, depreciation and amortization) results of $3.4 million, a significant improvement over the C$6.2 million loss in the same period last year. This is the company’s fourth consecutive quarter of positive EBITDA, demonstrating its financial stability and operational efficiency.
Miguel Martin, CEO of Aurora Cannabis, points to plans to further optimize costs and increase profitability. The company plans to achieve positive cash flow in the 2024 calendar year, an ambitious but realistic goal. The key here is the combination of industry-leading margins and a strong balance sheet, which opens Aurora Cannabis to new growth and acquisition opportunities.
Aurora Cannabis’ success is proof that medical cannabis is becoming an increasingly important part of the global pharmaceutical market. Product innovation, international expansion, and stable financial management are key to continued growth and success in this rapidly changing industry. The potential for medical cannabis is enormous, and companies like Aurora Cannabis are playing a key role in shaping the future of this market.
Poland faces the opportunity to become a key player in the growing global medical cannabis market. However, the current situation, in which the country does not produce its own, but only imports medical cannabis, puts Poland in the role of a passive observer rather than an active participant in this rapidly growing sector.
Read more on the subject and find the latest cannabis news of the day with the Hemp.im mobile app, available for free for both Android and iOS devices.
Cannabis import vs. domestic production: What is Poland losing as a country
1 Raising Costs for Patients:
Every step of importing – from transportation to intermediaries – affects the final price of the product. Patients in Poland have to pay higher costs for medical cannabis, making treatment less accessible, especially for those with limited financial resources.
2 Dependence on Foreign Suppliers:
Poland remains dependent on foreign companies and markets, such as Portugal, which is becoming a leader in exporting the product, when importing medical cannabis. This dependence limits Poland’s ability to negotiate prices and supply terms.
3 Lack of Support for the Domestic Economy:
Poland does not enjoy the economic benefits that domestic production would bring. The cultivation, processing, and sale of medical cannabis in Poland could create new jobs and impact economic growth.
4 Limited Research Opportunities:
With its own cultivation, Poland would have more opportunities to conduct research on medical cannabis. This research could contribute to the development of new, more effective therapies, as well as expand our knowledge of the plant.
Portugal as an example of appropriate policy
Portugal, with an impressive 1589kg of medical cannabis exports to Poland in the first half of 2023, shows how significant the industry’s potential is. Despite low domestic sales, the country is an example of how a strategic decision to invest in cultivation can benefit internationally.
Poland should consider revising its medical cannabis policy. The key here is not only to increase availability and lower costs for patients but also to capitalize on the economic potential the industry brings. Enabling domestic production and investing in research could have long-term benefits for both the economy and public health.
It is also essential to educate the public and medical professionals about the benefits of medical cannabis. Increased awareness and a better understanding of the subject could help change attitudes and policies towards the plant in Poland.
Poland faces the challenge of revising its strategy towards medical cannabis. Importing this plant, despite its simplicity of cultivation, not only generates additional costs for patients but also deprives Poland of the opportunity for internal market development, research, and economic benefits. It is time for Poland to move from being a passive importer to an active producer and innovator in the field of medical cannabis.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in FaktyKonopne. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Cann-L Project: First Legal Cannabis Dispensary Opens in Lausanne, Switzerland
In Cann-L store, recreational cannabis will be sold for between 9 and 12 Swiss francs per gram (40 - 55...
While the Gold Stocks Were Lower, They Were Not Trashed
Highlight of the week was the U.S. job numbers which came in higher than expected. However, there was another highlight...
Why the Entire Debt Market Is Seeing Declines in Yields
My recommendation on the debt market is to leave it alone and watch this show from afar. I say that...
Three Cheap Gold Stocks That’s Beating The Market
Although this year has presented investors with tremendous challenges, spot gold remains a buffer and potential hedge against inflation. Yet,...
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [++ KuCoin Affiliate Program Review]
This week, we answer the two questions on everyone’s lips — What do SJWs and e/accs have in common? And...
Crowdfunding2 weeks ago
Innexta and Assofintech Event Gathers 200 Investors to Meet Live Crowdinvesting Portals
Business6 days ago
Groupon Is Overhyped and Overexposed — Here’s Why RDE, Inc. Is a Better Alternative
Fintech2 weeks ago
After Obtaining Endorsement as a Fintech, Klu Will Seek to Become a Sofipo
Impact Investing4 days ago
Vortex Fights Food Waste in Italy